- Home
- ANIX vs IMAB Comparison
ANIX vs IMAB Comparison
Compare ANIX & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- IMAB
- Stock Information
- Founded
- ANIX 1982
- IMAB 2014
- Country
- ANIX United States
- IMAB United States
- Employees
- ANIX N/A
- IMAB N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- IMAB Health Care
- Exchange
- ANIX Nasdaq
- IMAB Nasdaq
- Market Cap
- ANIX 88.9M
- IMAB 73.9M
- IPO Year
- ANIX 1987
- IMAB 2020
- Fundamental
- Price
- ANIX $3.38
- IMAB $2.50
- Analyst Decision
- ANIX Strong Buy
- IMAB Strong Buy
- Analyst Count
- ANIX 3
- IMAB 2
- Target Price
- ANIX $9.00
- IMAB $5.50
- AVG Volume (30 Days)
- ANIX 236.6K
- IMAB 1.0M
- Earning Date
- ANIX 05-28-2025
- IMAB 05-15-2025
- Dividend Yield
- ANIX N/A
- IMAB N/A
- EPS Growth
- ANIX N/A
- IMAB N/A
- EPS
- ANIX N/A
- IMAB N/A
- Revenue
- ANIX N/A
- IMAB N/A
- Revenue This Year
- ANIX N/A
- IMAB N/A
- Revenue Next Year
- ANIX N/A
- IMAB N/A
- P/E Ratio
- ANIX N/A
- IMAB N/A
- Revenue Growth
- ANIX N/A
- IMAB N/A
- 52 Week Low
- ANIX $2.07
- IMAB $0.60
- 52 Week High
- ANIX $4.20
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- ANIX 57.87
- IMAB 67.42
- Support Level
- ANIX $3.30
- IMAB $2.29
- Resistance Level
- ANIX $3.80
- IMAB $2.69
- Average True Range (ATR)
- ANIX 0.25
- IMAB 0.35
- MACD
- ANIX 0.05
- IMAB 0.00
- Stochastic Oscillator
- ANIX 61.47
- IMAB 64.53
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).